

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2022/094462 A1

(43) International Publication Date
05 May 2022 (05.05.2022)

(51) International Patent Classification:

A61K 31/165 (2006.01) A61K 31/439 (2006.01)
A61K 31/4164 (2006.01)

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

(21) International Application Number:

PCT/US2021/057720

Published:

— with international search report (Art. 21(3))

(22) International Filing Date:

02 November 2021 (02.11.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/108,720 02 November 2020 (02.11.2020) US
63/162,367 17 March 2021 (17.03.2021) US
63/257,024 18 October 2021 (18.10.2021) US

(71) Applicant: **VISUS THERAPEUTICS, INC.** [US/US]; 2
Nickerson Street, Suite 101, Seattle, Washington 98109
(US).

(72) Inventors: **SCHIFFMAN, Rhett Mead**; 1970 Temple
Hills Drive, Laguna Beach, California 92651 (US). **FIRES-
TONE, Bruce Alan**; 18 Cedar Ridge, Irvine, California
92603 (US).

(74) Agent: **GILLENLINE, Marsha Rose** et al.; Sterne,
Kessler, Goldstein & Fox P.L.L.C., 1100 New York Avenue,
NW, Washington, District of Columbia 20005 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: DEGRADANT COMPOUND IN A MEDICAMENT

(57) Abstract: The present disclosure is directed to ophthalmic formulations comprising carbachol, brimonidine, and less than 5% of one or more impurities, processes for preparing ophthalmic formulations comprising carbachol, brimonidine, and less than 5% of one or more impurities, and methods of treating presbyopia and other ophthalmic conditions by administering ophthalmic formulations comprising carbachol, brimonidine, and less than 5% of one or more impurities.

WO 2022/094462 A1